A Phase 2 interventional study of cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma, sponsored by Regeneron Pharmaceuticals. Completed at 78 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goals of this study are to evaluate the clinical benefit and safety of cemiplimab in participants with metastatic (nodal or distant) Cutaneous Squamous Cell Carcinoma (CSCC), or unresectable locally advanced CSCC.
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received cemiplimab 3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks (Q2W) during each 8-week treatment cycle, for up to 96 weeks (12 cycles).
Drug: cemiplimab
Participants received cemiplimab 3 mg/kg IV Q2W during each 8-week treatment cycle, for up to 96 weeks (12 cycles).
Drug: cemiplimab
Participants received cemiplimab 350 mg IV every 3 weeks (Q3W) during each 9-week treatment cycle, for up to 54 weeks (6 cycles).
Drug: cemiplimab
Participants received cemiplimab 600 mg IV every 4 weeks (Q4W) during each 8-week treatment cycle, for up to 48 weeks (6 cycles).
Drug: cemiplimab
Participants received a single subcutaneous (SC) dose of cemiplimab followed by cemiplimab 350 mg IV Q3W during each 9-week treatment cycle, for up to 54 weeks (6 cycles).
Drug: cemiplimab
Participants received cemiplimab 350 mg IV Q3W during each 9-week treatment cycle, for up to 108 weeks (12 cycles).
Drug: cemiplimab
Also known as: REGN2810, Libtayo
Overall Response Rate (ORR) by Independent Central Review
ORR was defined as percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR). For participants with metastatic disease, Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) \<1 (centimeter (cm). -PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Clinical Response Criteria: -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.
Time frame: Up to 108 weeks
ORR by Investigator Assessment
ORR was defined as percentage of participants with BOR of CR or PR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm \<1 cm. -PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Clinical Response Criteria: -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.
Time frame: Up to 108 weeks
Duration of Response (DOR) by Independent Central Review
DOR was measured from the time measurement criteria were first met for CR/PR, whichever was recorded first, until the first date of recurrent or Progressive Disease (PD) or death due to any cause in participants with BOR of CR or PR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.
Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)
DOR by Investigator Assessment
DOR was measured from the time measurement criteria were first met for CR/PR, as defined in Outcome Measure 1, whichever was recorded first, until the first date of recurrent or Progressive Disease (PD) or death due to any cause in participants with BOR of CR or PR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (World Health Organization (WHO) criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.
Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)
Progression-Free Survival (PFS) by Independent Central Review
PFS was measured from start of treatment until the first date of recurrent or PD, or death due to any cause. For participants with metastatic disease, RECIST v1.1 was used to determine PD. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.
Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)
PFS by Investigator Assessment
PFS was measured from start of treatment until the first date of recurrent or PD, or death due to any cause. For participants with metastatic disease, RECIST v1.1 was used to determine PD. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.
Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)
Overall Survival (OS)
OS was measured from start of treatment until death due to any cause.
Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)
Complete Response (CR) Rate by Independent Central Review
CR rate was defined as percentage of participants with BOR of CR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm \<1 cm. Clinical Response Criteria: -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions.
Time frame: Up to 108 weeks
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Score
EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.
Time frame: Baseline, Up to Cycle 12 Day 1 (Week 89)
Number of Participants With Any Treatment Emergent Adverse Event (TEAE)
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious Adverse Events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. Treatment-emergent adverse events (TEAEs) are defined as those not present at baseline or represent the exacerbation of a condition present at baseline during the on-treatment period or follow-up period. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Up to 108 weeks plus 105 days (5 half-lives)
Peak Concentration (Cmax) of Cemiplimab
Time frame: Up to approximately 43 months
Trough Concentration (Ctrough) of Cemiplimab
Time frame: Up to approximately 43 months
Number of Participants With Treatment-Emergent Anti-cemiplimab Antibodies
Time frame: Up to approximately 43 months
ORR by Independent Central Review for Participants With Evaluable PD-L1 Assays
ORR was defined as percentage of participants with BOR of CR or PR. Expression level of PD-L1 was assessed in tumor biopsy samples by immunohistochemistry (IHC). -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.
Time frame: Up to 108 weeks
DOR by Independent Central Review for Participants With Evaluable PD-L1 Assays
DOR was measured from the time measurement criteria are first met for CR/PR, as defined in Outcome Measure 13, whichever was recorded first, until the first date of recurrent or PD or death due to any cause in participants with BOR of CR or PR. Expression level of PD-L1 was assessed in tumor biopsy samples by IHC. -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.
Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)
PFS by Independent Central Review for Participants With Evaluable PD-L1 Assays
PFS was measured from time of enrollment until the first date of recurrent or progressive disease, or death due to any cause. Expression level of PD-L1 was assessed in tumor biopsy samples. -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.
Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)
| Milestone | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|---|---|---|---|---|
| Started | 59 | 78 | 56 | 63 | 9 | 167 |
| Received at least 1 dose of study drug | 59 | 78 | 56 | 63 | 9 | 165 |
| Completed treatment | 24 | 20 | 22 | 27 | 5 | 50 |
| Completed | 19 | 28 | 22 | 24 | 3 | 64 |
| Not completed | 40 | 50 | 34 | 39 | 6 | 103 |
| Withdrew: Adverse event | 3 | 3 | 1 | 1 | 0 | 6 |
| Withdrew: Death | 7 | 5 | 5 | 7 | 0 | 23 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Non-compliance with study drug | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Participant decision | 1 | 4 | 2 | 2 | 1 | 6 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 3 | 0 | 0 |
| Withdrew: Physician decision | 3 | 4 | 1 | 4 | 0 | 2 |
| Withdrew: Disease progression | 21 | 19 | 20 | 18 | 4 | 55 |
| Withdrew: Withdrawal by subject | 4 | 7 | 5 | 1 | 0 | 6 |
| Withdrew: Other than specified | 1 | 6 | 0 | 3 | 1 | 0 |
| Withdrew: Not treated | 0 | 0 | 0 | 0 | 0 | 2 |
ORR was defined as percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR). For participants with metastatic disease, Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) \<1 (centimeter (cm). -PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Clinical Response Criteria: -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.
| percentage of participants | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) by Independent Central Review | 50.8 (37.5 to 64.1) | 44.9 (33.6 to 56.6) | 46.4 (33.0 to 60.3) | 61.9 (48.8 to 73.9) | 47.3 (39.5 to 55.2) |
ORR was defined as percentage of participants with BOR of CR or PR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm \<1 cm. -PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Clinical Response Criteria: -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.
| percentage of participants | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|---|---|---|---|
| ORR by Investigator Assessment | 50.8 (37.5 to 64.1) | 56.4 (44.7 to 67.6) | 55.4 (41.5 to 68.7) | 63.5 (50.4 to 75.3) | 52.7 (44.8 to 60.5) |
DOR was measured from the time measurement criteria were first met for CR/PR, whichever was recorded first, until the first date of recurrent or Progressive Disease (PD) or death due to any cause in participants with BOR of CR or PR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.
| months | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|---|---|---|---|
| Duration of Response (DOR) by Independent Central Review | NA (20.7 to NA) | 41.9 (20.5 to 54.6) | 41.3 (40.8 to 46.3) | NA (30.5 to NA) | 31.6 (29.5 to NA) |
DOR was measured from the time measurement criteria were first met for CR/PR, as defined in Outcome Measure 1, whichever was recorded first, until the first date of recurrent or Progressive Disease (PD) or death due to any cause in participants with BOR of CR or PR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (World Health Organization (WHO) criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.
| months | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|---|---|---|---|
| DOR by Investigator Assessment | NA (30.7 to NA) | 41.9 (NA to NA) | 44.2 (25.4 to 44.2) | NA (27.1 to NA) | NA (29.5 to NA) |
PFS was measured from start of treatment until the first date of recurrent or PD, or death due to any cause. For participants with metastatic disease, RECIST v1.1 was used to determine PD. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.
| months | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) by Independent Central Review | 18.4 (7.3 to 53.2) | 18.5 (11.1 to 43.8) | 21.7 (3.8 to 43.3) | 32.2 (16.6 to NA) | 16.6 (12.4 to 31.5) |
PFS was measured from start of treatment until the first date of recurrent or PD, or death due to any cause. For participants with metastatic disease, RECIST v1.1 was used to determine PD. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.
| months | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|---|---|---|---|
| PFS by Investigator Assessment | 16.6 (7.3 to NA) | 32.5 (17.1 to 43.8) | 15.2 (4.1 to 43.0) | 25.3 (8.2 to NA) | 16.5 (10.3 to 31.3) |
OS was measured from start of treatment until death due to any cause.
| months | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|---|---|---|---|
| Overall Survival (OS) | 57.7 (29.3 to NA) | NA (58.3 to NA) | 48.4 (29.5 to NA) | NA (28.6 to NA) | NA (NA to NA) |
CR rate was defined as percentage of participants with BOR of CR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm \<1 cm. Clinical Response Criteria: -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions.
| percentage of participants | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|---|---|---|---|
| Complete Response (CR) Rate by Independent Central Review | 20.3 (11.0 to 32.8) | 12.8 (6.3 to 22.3) | 19.6 (10.2 to 32.4) | 22.2 (12.7 to 34.5) | 10.8 (6.5 to 16.5) |
EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.
| score on a scale | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W |
|---|---|---|---|---|
| Cycle 2 Day 1 (C2D1) | 0.00 ± 21.464 | 5.56 ± 18.895 | 6.86 ± 19.621 | 0.96 ± 17.670 |
| C3D1 | 11.26 ± 19.267 | 5.30 ± 21.717 | 15.28 ± 20.655 | 3.88 ± 15.680 |
| C4D1 | 6.25 ± 25.069 | 8.76 ± 19.585 | 13.51 ± 22.539 | 4.39 ± 15.099 |
| C5D1 | 4.17 ± 22.316 | 8.33 ± 21.246 | 13.27 ± 21.466 | 5.79 ± 18.774 |
| C6D1 | 5.11 ± 17.437 | 5.68 ± 28.118 | 12.18 ± 24.521 | 0.25 ± 21.599 |
| C7D1 | 6.51 ± 17.676 | 9.17 ± 22.393 | 22.22 ± 23.659 | 4.44 ± 18.598 |
| C8D1 | 4.60 ± 21.080 | 10.10 ± 21.425 | 30.30 ± 19.816 | 5.00 ± 25.158 |
| C9D1 | 6.09 ± 18.938 | 6.61 ± 26.199 | 26.67 ± 24.470 | 7.69 ± 20.543 |
| C10D1 | 12.04 ± 20.844 | 13.77 ± 26.064 | 28.70 ± 13.889 | 5.83 ± 22.923 |
| C11D1 | 10.33 ± 28.186 | 11.40 ± 22.603 | 32.50 ± 14.407 | 14.81 ± 19.444 |
| C12D1 | 8.33 ± 22.388 | 12.75 ± 24.494 | 27.78 ± 16.667 | 2.78 ± 26.021 |
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious Adverse Events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. Treatment-emergent adverse events (TEAEs) are defined as those not present at baseline or represent the exacerbation of a condition present at baseline during the on-treatment period or follow-up period. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|---|---|---|---|---|
| Number of Participants With Any Treatment Emergent Adverse Event (TEAE) | 59 | 78 | 55 | 63 | 9 | 163 |
| milligram per liter (mg/L) | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|---|---|---|---|---|
| After the First Dose | 108 ± 147 | 84.1 ± 105 | 132 ± 203 | 174 ± 50.1 | 52.9 ± 18.4 | 96.3 ± 56.2 |
| At Steady State | 151 ± 83.7 | 148 ± 76.6 | 151 ± 46.2 | 281 ± 235 | 174 ± 62.2 | 142 ± 78.3 |
| mg/L | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|---|---|---|---|---|
| After the First Dose | 21.5 ± 7.12 | 26.3 ± 14.3 | 33.6 ± 32.1 | 32.1 ± 10.4 | 34.1 ± 14.1 | 23.0 ± 10.9 |
| At Steady State | 69.9 ± 19.3 | 67.5 ± 29.8 | 62.7 ± 28.3 | 62.5 ± 24.1 | 65.9 ± 22.9 | 53.3 ± 20.1 |
| Participants | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Anti-cemiplimab Antibodies | 1 | 0 | 0 | 0 | 0 | 5 |
ORR was defined as percentage of participants with BOR of CR or PR. Expression level of PD-L1 was assessed in tumor biopsy samples by immunohistochemistry (IHC). -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.
| percentage of participants | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|
| PD-L1 < 1% | 40.5 (24.8 to 57.9) |
| PD-L1 >= 1% | 49.2 (35.9 to 62.5) |
DOR was measured from the time measurement criteria are first met for CR/PR, as defined in Outcome Measure 13, whichever was recorded first, until the first date of recurrent or PD or death due to any cause in participants with BOR of CR or PR. Expression level of PD-L1 was assessed in tumor biopsy samples by IHC. -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.
| months | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|
| PD-L1 < 1% | 31.6 (12.6 to NA) |
| PD-L1 >= 1% | NA (NA to NA) |
PFS was measured from time of enrollment until the first date of recurrent or progressive disease, or death due to any cause. Expression level of PD-L1 was assessed in tumor biopsy samples. -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.
| months | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W |
|---|---|
| PD-L1 < 1% | 10.7 (3.0 to 15.3) |
| PD-L1 >= 1% | 16.6 (4.0 to NA) |
Collected over From signing of informed consent through end of study up to approximately 65 months (treatment period + follow-up including survival follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 27/59 (45.8%) | 24/59 (40.7%) | 56/59 (94.9%) |
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 19/78 (24.4%) | 28/78 (35.9%) | 75/78 (96.2%) |
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 26/56 (46.4%) | 23/56 (41.1%) | 49/56 (87.5%) |
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 23/63 (36.5%) | 35/63 (55.6%) | 59/63 (93.7%) |
| Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | 2/9 (22.2%) | 2/9 (22.2%) | 9/9 (100%) |
| Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W | 59/165 (35.8%) | 85/165 (51.5%) | 147/165 (89.1%) |
| Group 6a (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W to 350 mg SC Q3W | 2/12 (16.7%) | 4/12 (33.3%) | 9/12 (75%) |
| Group 6b (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W to 1050 mg SC Q6W | 0/7 (0%) | 1/7 (14.3%) | 5/7 (71.4%) |
| Event | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W | Group 6a (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W to 350 mg SC Q3W | Group 6b (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W to 1050 mg SC Q6W |
|---|---|---|---|---|---|---|---|---|
| ColitisGastrointestinal disorders | 0/59 | 0/78 | 0/56 | 0/63 | 2/9 | 0/165 | 0/12 | 0/7 |
| Myocardial ischaemiaCardiac disorders | 0/59 | 0/78 | 0/56 | 0/63 | 0/9 | 0/165 | 0/12 | 1/7 |
| Pneumonia aspirationInfections and infestations | 0/59 | 1/78 | 0/56 | 0/63 | 0/9 | 0/165 | 1/12 | 0/7 |
| Urinary tract infectionInfections and infestations | 1/59 | 1/78 | 1/56 | 0/63 | 0/9 | 1/165 | 1/12 | 0/7 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 4/59 | 4/78 | 1/56 | 1/63 | 0/9 | 0/165 | 1/12 | 0/7 |
| Skin lacerationInjury, poisoning and procedural complications | 0/59 | 0/78 | 0/56 | 1/63 | 0/9 | 1/165 | 1/12 | 0/7 |
| Myocardial infarctionCardiac disorders | 1/59 | 1/78 | 0/56 | 2/63 | 0/9 | 2/165 | 1/12 | 0/7 |
| HyponatraemiaMetabolism and nutrition disorders | 0/59 | 0/78 | 0/56 | 0/63 | 0/9 | 1/165 | 1/12 | 0/7 |
| CellulitisInfections and infestations | 4/59 | 2/78 | 1/56 | 1/63 | 0/9 | 2/165 | 0/12 | 0/7 |
| PneumoniaInfections and infestations | 2/59 | 5/78 | 0/56 | 3/63 | 0/9 | 7/165 | 0/12 | 0/7 |
| Event | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W | Group 6a (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W to 350 mg SC Q3W | Group 6b (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W to 1050 mg SC Q6W |
|---|---|---|---|---|---|---|---|---|
| Rash maculo-papularSkin and subcutaneous tissue disorders | 9/59 | 8/78 | 7/56 | 8/63 | 4/9 | 18/165 | 0/12 | 0/7 |
| FatigueGeneral disorders | 15/59 | 34/78 | 17/56 | 14/63 | 1/9 | 44/165 | 1/12 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 17/59 | 23/78 | 13/56 | 17/63 | 3/9 | 39/165 | 0/12 | 1/7 |
| RashSkin and subcutaneous tissue disorders | 11/59 | 11/78 | 10/56 | 12/63 | 3/9 | 11/165 | 0/12 | 0/7 |
| Upper respiratory tract infectionInfections and infestations | 6/59 | 9/78 | 5/56 | 8/63 | 3/9 | 0/165 | 0/12 | 0/7 |
| COVID-19Infections and infestations | 0/59 | 0/78 | 0/56 | 0/63 | 0/9 | 13/165 | 4/12 | 0/7 |
| PruritusSkin and subcutaneous tissue disorders | 11/59 | 23/78 | 7/56 | 16/63 | 1/9 | 43/165 | 1/12 | 0/7 |
| Actinic keratosisSkin and subcutaneous tissue disorders | 4/59 | 12/78 | 7/56 | 8/63 | 0/9 | 17/165 | 2/12 | 2/7 |
| Blood creatinine increasedInvestigations | 4/59 | 5/78 | 5/56 | 7/63 | 1/9 | 0/165 | 0/12 | 2/7 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/59 | 10/78 | 3/56 | 6/63 | 0/9 | 14/165 | 2/12 | 2/7 |
The Full Analysis Set (FAS) included all enrolled participants.
| Age, Customized(Participants) | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W | Total |
|---|---|---|---|---|---|---|---|
| < 65 years | 16 | 19 | 14 | 16 | 3 | 30 | 98 |
| >= 65 to < 75 years | 23 | 23 | 20 | 17 | 4 | 43 | 130 |
| >= 75 years | 20 | 36 | 22 | 30 | 2 | 94 | 204 |
| Sex: Female, Male(Participants) | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W | Total |
|---|---|---|---|---|---|---|---|
| Female | 5 | 19 | 8 | 10 | 4 | 37 | 83 |
| Male | 54 | 59 | 48 | 53 | 5 | 130 | 349 |
| Ethnicity (NIH/OMB)(Participants) | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 1 | 1 | 0 | 4 | 9 |
| Not Hispanic or Latino | 58 | 75 | 55 | 62 | 8 | 147 | 405 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 | 16 | 18 |
| Race (NIH/OMB)(Participants) | Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W | Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 | 2 | 1 | 0 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 58 | 75 | 54 | 61 | 8 | 164 | 420 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 3 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2016 to primary completion in Oct 2023, 90 months.
Results were first posted in Dec 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab